Edition:
United Kingdom

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

6.06USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$6.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
782,524
52-wk High
$8.84
52-wk Low
$1.53

Select another date:

Fri, Nov 3 2017

BRIEF-ImmunoGen reports Q3 loss per share $0.61

* ImmunoGen reports recent progress and third quarter 2017 operating results

BRIEF-Immunogen announces investigational new drug application for IMGN632 for hematological malignancies is active

* Immunogen announces investigational new drug application for IMGN632 for hematological malignancies is active

BRIEF-Immunogen prices offering of 14.5 mln common shares at $6.50 per share

* Immunogen announces pricing of public offering of common stock

BRIEF-Immunogen- As of Sept. 30, had cash and cash equivalents of about $194.9 mln

* Immunogen- on Oct, 4,, co disclosed that it expects to report that as of Sept. 30, 2017 it had cash and cash equivalents of about $194.9 million Source: (http://bit.ly/2gcIozK) Further company coverage:

BRIEF-ImmunoGen intends to offer and sell 13 mln shares of common stock​

* ImmunoGen announces proposed public offering of common stock

BRIEF-Immunogen enters privately negotiated exchange agreements

* Immunogen-‍on Sept 25, co entered privately negotiated exchange agreements with some holders of co's outstanding 4.50% convertible senior notes due 2021​

BRIEF-ImmunoGen announces agreements to exchange $76.4 mln of its 4.5 pct convertible senior notes due 2021 for common stock

* ImmunoGen announces agreements to exchange $76.4 million of its 4.50% convertible senior notes due 2021 for common stock

BRIEF-Jazz Pharmaceuticals and Immunogen sign deal to develop, commercialize antibody-drug conjugate products

* Jazz Pharmaceuticals and Immunogen inc announce a strategic collaboration and option agreement to develop and commercialize antibody-drug conjugate products

BRIEF-Jazz Pharmaceuticals and Immunogen announce strategic collaboration and option agreement

* Jazz Pharmaceuticals and Immunogen Inc announce a strategic collaboration and option agreement to develop and commercialize antibody-drug conjugate products Source text for Eikon: Further company coverage:

BRIEF-Polygon Management Ltd reports 5.2 pct passive stake in Immunogen Inc - SEC Filing

* Polygon Management Ltd reports 5.2 percent passive stake in Immunogen Inc, as of August 2, 2017 - SEC Filing Source text: (http://bit.ly/2uAaTff) Further company coverage:

Select another date: